MedTrace Logo

A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).

NCT05240131 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2024-04-12

No results posted yet for this study

Summary

This study is an open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).

Conditions

Interventions

DRUG

Atezolizumab

Atezolizumab is an PD-L1 inhibitor administered as an intravenous infusion every three weeks at a dose of 1200mg

DRUG

GB1211

GB1211 is a galectin 3 inhibitor an orally available small molecular anti-fibrotic. It is administered orally twice a day.

DRUG

Placebo

Placebo is administered orally twice a day.

Sponsors & Collaborators

  • Linical Europe GmbH

    collaborator UNKNOWN

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Galecto Biotech AB

    lead INDUSTRY

Principal Investigators

  • Francois Ghiringhelli, MD · Centre Georges Grancois Leclerc, Dijon

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-15
Primary Completion
2024-05-30
Completion
2025-11-01

Countries

  • France
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05240131 on ClinicalTrials.gov